Tirucallic acids are novel pleckstrin homology domain-dependent akt inhibitors inducing apoptosis in prostate cancer cells

Molecular Pharmacology

Volumn 77, Issue 3, 2010, Pages 378-387

  Estrada, Aydee C ^a   Syrovets, Tatiana ^a   Pitterle, Kai ^a   Lunov, Oleg ^a   Büchele, Berthold ^a   Schimana Pfeifer, Judith ^a   Schmidt, Thomas ^a   Morad, Samy A F ^a   Simmet, Thomas ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 ALPHA ACETOXYTIRUCALLIC ACID; 3 BETA ACETOXYTIRUCALLIC ACID; 3 OXO TIRUCALLIC ACID; ANDROGEN RECEPTOR; BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3BETA; I KAPPA B KINASE; MYC PROTEIN; PHOSPHATIDYLINOSITOL; PROTEIN AKT1; PROTEIN BAD; PROTEIN KINASE B; PROTEIN KINASE B BETA; PROTEIN KINASE B INHIBITOR; SYNAPTOTAGMIN I; TIRUCALLIC ACID DERIVATIVE; TRITERPENOID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BOSWELLIA; CANCER CELL CULTURE; CELL STRAIN LNCAP; CHORIOALLANTOIS; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HYDROGEN BOND; MALE; MOUSE; NONHUMAN; PLECKSTRIN HOMOLOGY DOMAIN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; STRUCTURE ANALYSIS; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING SITES; BLOOD PROTEINS; BOSWELLIA; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MICE; MICE, NUDE; PHOSPHOPROTEINS; PLANT EXTRACTS; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; TRITERPENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77149153396     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.060475     Document Type: Article

References (50)

1. Akihisa T, Tabata K, Banno N, Tokuda H, Nishimura R, Nakamura Y, Kimura Y, Yasukawa K, and Suzuki T (2006) Cancer chemopreventive effects and cytotoxic activities of the triterpene acids from the resin of Boswellia carteri. Biol Pharm Bull 29:1976-1979.
2. Amaravadi R and Thompson CB (2005) The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 115:2618-2624.
3. Armstrong AJ and Carducci MA (2006) New drugs in prostate cancer. Curr Opin Urol 16:138-145.
4. Bailly C (2009) Ready for a comeback of natural products in oncology. Biochem Pharmacol 77:1447-1457.
5. Büchele B, Zugmaier W, and Simmet T (2003) Analysis of pentacyclic triterpenic acids from frankincense gum resins and related phytopharmaceuticals by highperformance liquid chromatography. Identification of lupeolic acid, a novel pentacyclic triterpene. J Chromatogr B Analyt Technol Biomed Life Sci 791:21-30.
6. Burysek L, Syrovets T, and Simmet T (2002) The serine protease plasmin triggers expression of MCP-1 and CD40 in human primary monocytes via activation of p38 MAPK and janus kinase (JAK)/STAT signaling pathways. J Biol Chem 277: 33509-33517.
7. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, Uhlik M, Lin A, Du J, Qian YW, Zeckner DJ, Tucker-Kellogg G, Touchman J, Patel K, Mousses S, Bittner M, Schevitz R, Lai MH, Blanchard KL, and Thomas JE (2007) A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448:439-444.
8. Chang DC, Gao PQ, and Maxwell BL (1991) High efficiency gene transfection by electroporation using a radio-frequency electric field. Biochim Biophys Acta 1092: 153-160.
9. Cheng JQ, Lindsley CW, Cheng GZ, Yang H, and Nicosia SV (2005) The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 24:7482-7492.
10. Colognato R, Slupsky JR, Jendrach M, Burysek L, Syrovets T, and Simmet T (2003) Differential expression and regulation of protease-activated receptors in human peripheral monocytes and monocyte-derived antigen-presenting cells. Blood 102: 2645-2652.
11. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, and Li F (2006) The c-Myc target gene network. Semin Cancer Biol 16:253-264.
12. Datta K, Franke TF, Chan TO, Makris A, Yang SI, Kaplan DR, Morrison DK, Golemis EA, and Tsichlis PN (1995) AH/PH domain-mediated interaction between Akt molecules and its potential role in Akt regulation. Mol Cell Biol 15:2304-2310.
13. Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9:550-562.
14. Faivre S, Djelloul S, and Raymond E (2006) New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 33: 407-420.
15. Gajate C and Mollinedo F (2007) Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 109:711-719.
16. Garcia-Echeverria C and Sellers WR (2008) Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 27:5511-5526.
17. Guan KL, Figueroa C, Brtva TR, Zhu T, Taylor J, Barber TD, and Vojtek AB (2000) Negative regulation of the serine/threonine kinase B-Raf by Akt. J Biol Chem 275:27354-27359.
18. Gustin JA, Ozes ON, Akca H, Pincheira R, Mayo LD, Li Q, Guzman JR, Korgaonkar CK, and Donner DB (2004) Cell type-specific expression of the IκB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-κB activation. J Biol Chem 279:1615-1620.
19. Héron-Milhavet L, Franckhauser C, Rana V, Berthenet C, Fisher D, Hemmings BA, Fernandez A, and Lamb NJ (2006) Only Akt1 is required for proliferation, while Akt2 promotes cell cycle exit through p21 binding. Mol Cell Biol 26:8267-8280.
20. Hetényi C and van der Spoel D (2002) Efficient docking of peptides to proteins without prior knowledge of the binding site. Protein Sci 11:1729-1737.
21. Higuchi M, Masuyama N, Fukui Y, Suzuki A, and Gotoh Y (2001) Akt mediates Rac/Cdc42-regulated cell motility in growth factor-stimulated cells and in invasive PTEN knockout cells. Curr Biol 11:1958-1962.
22. Hiromura M, Okada F, Obata T, Auguin D, Shibata T, Roumestand C, and Noguchi M (2004) Inhibition of Akt kinase activity by a peptide spanning the βA strand of the proto-oncogene TCL1. J Biol Chem 279:53407-53418.
23. Irie HY, Pearline RV, Grueneberg D, Hsia M, Ravichandran P, Kothari N, Natesan S, and Brugge JS (2005) Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol 171:1023-1034.
24. Katoh N, Kraft S, Wessendorf JH, and Bieber T (2000) The high-affinity IgE receptor (FcεRI) blocks apoptosis in normal human monocytes. J Clin Invest 105:183-190.
25. Kau TR, Schroeder F, Ramaswamy S, Wojciechowski CL, Zhao JJ, Roberts TM, Clardy J, Sellers WR, and Silver PA (2003) A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell 4:463-476.
26. Lemmon MA (2004) Pleckstrin homology domains: not just for phosphoinositides. Biochem Soc Trans 32:707-711.
27. Li L, Ittmann MM, Ayala G, Tsai MJ, Amato RJ, Wheeler TM, Miles BJ, Kadmon D, and Thompson TC (2005) The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis 8:108-118.
28. Lindsley CW, Zhao Z, Leister WH, Robinson RG, Barnett SF, Defeo-Jones D, Jones RE, Hartman GD, Huff JR, Huber HE, and Duggan ME (2005) Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett 15:761-764.
29. Liu P, Cheng H, Roberts TM, and Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8:627-644.
30. Majumder PK and Sellers WR (2005) Akt-regulated pathways in prostate cancer. Oncogene 24:7465-7474.
31. Martelli AM, Faenza I, Billi AM, Manzoli L, Evangelisti C, Falà F, and Cocco L (2006) Intranuclear 3′-phosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis? Cell Signal 18:1101-1107.
32. Mende I, Malstrom S, Tsichlis PN, Vogt PK, and Aoki M (2001) Oncogenic transformation induced by membrane-targeted Akt2 and Akt3. Oncogene 20:4419-4423.
33. Morgan TM, Koreckij TD, and Corey E (2009) Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets 9:237-249.
34. Morris MM, Goodsell DS, Halliday RS, Huey R, Hart WH, Belew RK, and Olson AJ (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19:1639-1662.
35. Nakatani K, Thompson DA, Barthel A, Sakaue H, Liu W, Weigel RJ, and Roth RA (1999) Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 274:21528-21532.
36. Newman DJ and Cragg GM (2007) Natural products as sources of new drugs over the last 25 years. J Nat Prod 70:461-477.
37. Posadas EM, Gulley J, Arlen PM, Trout A, Parnes HL, Wright J, Lee MJ, Chung EJ, Trepel JB, Sparreboom A, Chen C, Jones E, Steinberg SM, Daniels A, Figg WD, and Dahut WL (2005) A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol Ther 4:1133-1137.
38. Rong SB, Hu Y, Enyedy I, Powis G, Meuillet EJ, Wu X, Wang R, Wang S, and Kozikowski AP (2001) Molecular modeling studies of the Akt PH domain and its interaction with phosphoinositides. J Med Chem 44:898-908.
39. Stambolic V and Woodgett JR (2006) Functional distinctions of protein kinase B/Akt isoforms defined by their influence on cell migration. Trends Cell Biol 16:461-466.
40. Syrovets T, Büchele B, Gedig E, Slupsky JR, and Simmet T (2000) Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and IIα. Mol Pharmacol 58:71-81.
41. Syrovets T, Büchele B, Krauss C, Laumonnier Y, and Simmet T (2005a) Acetylboswellic acids inhibit lipopolysaccharide-mediated TNF-α induction in monocytes by direct interaction with IκB kinases. J Immunol 174:498-506.
42. Syrovets T, Gschwend JE, Büchele B, Laumonnier Y, Zugmaier W, Genze F, and Simmet T (2005b) Inhibition of IκB kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo. J Biol Chem 280:6170-6180.
43. Syrovets T, Jendrach M, Rohwedder A, Schüle A, and Simmet T (2001) Plasmininduced expression of cytokines and tissue factor in human monocytes involves AP-1 and IKKβ-mediated NF-κB activation. Blood 97:3941-3950.
44. Syrovets T, Tippler B, Rieks M, and Simmet T (1997) Plasmin is a potent and specific chemoattractant for human peripheral monocytes acting via a cyclic guanosine monophosphate-dependent pathway. Blood 89:4574-4583.
45. Thimmaiah KN, Easton JB, Germain GS, Morton CL, Kamath S, Buolamwini JK, and Houghton PJ (2005) Identification of N10-substituted phenoxazines as potent and specific inhibitors of Akt signaling. J Biol Chem 280:31924-31935.
46. Thomas CC, Deak M, Alessi DR, and van Aalten DM (2002) High-resolution structure of the pleckstrin homology domain of protein kinase b/akt bound to phosphatidylinositol (3,4,5)-trisphosphate. Curr Biol 12:1256-1262.
47. Thomsen R and Christensen MH (2006) MolDock: a new technique for high-accuracy molecular docking. J Med Chem 49:3315-3321.
48. Toker A (2002) Phosphoinositides and signal transduction. Cell Mol Life Sci 59:761-779.
49. van den Hoff MJ, Moorman AF, and Lamers WH (1992) Electroporation in 'intracellular' buffer increases cell survival. Nucleic Acids Res 20:2902.
50. Zhao H, Dupont J, Yakar S, Karas M, and LeRoith D (2004) PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene 23:786-794.